New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
07:20 EDTTBIOTransgenomic announces issuance of new COLD-PCR technologies patent
Transgenomic announced that the European Patent Office has issued a new patent, European Patent No. 21833798, covering one of its COLD-PCR family of DNA amplification technologies. The patent covers Full COLD-PCR. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and exclusively licensed to Transgenomic. The new European patent helps extend the scope and longevity of the COLD-PCR intellectual property portfolio, which was originally developed by the laboratory of Mike Makrigiorgos at the Dana-Farber Cancer Institute. Transgenomic is also pursuing additional European patent coverage specific to ICE COLD-PCR technology.
News For TBIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2016
07:34 EDTTBIOTransgenomic says Multiplexed ICE COLD-PCR enables personalized medicine R&D
Transgenomic announced that Ben Legendre, Jr., PhD, Vice President, Laboratory Operations, delivered a presentation yesterday at the Personalized Medicine World Conference. In his talk, Legendre highlighted how Transgenomic's Multiplexed ICE COLD-PCR technology enables personalized medicine R&D, exemplified by its utility for stratification of clinical study patients in partnership with Transgenomic's pharmaceutical and biotechnology clients. In addition, the accuracy of MX-ICP and its ability to enable use of liquid biopsies are supporting the rapidly growing use of personalized and precision medicine strategies in routine clinical practice. In his talk, Legendre described how MX-ICP delivers enrichment of gene regions that allows determination of all point mutations and insertions/deletions. He noted that the ability of MX-ICP to efficiently detect genetic alterations down to 0.01% in blood and tissue samples and to increase the sensitivity of almost all downstream analysis platforms serve to make efficient detection of mutations feasible and practical for most laboratories. And the multiplexed format of MX-ICP allows sensitive detection and monitoring of all genetic alterations in multiple targets using a single DNA sample.
January 25, 2016
17:12 EDTTBIOTransgenomic files to sell 1.11M shares of common stock for holders
Subscribe for More Information
16:54 EDTTBIOTransgenomic files to sell 7.12M shares of common stock for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use